1-8 of 8
Brian J. Druker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy

Fieke W. Hoff, William G. Blum, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L. Lin, Kellie J. Archer, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, Martha L. Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca L. Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K. Curran, Kristin L. Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja G. Marcus, Leonard Rosenberg, Brian J. Druker, Ross L. Levine, Amy Burd, Ashley O. Yocum, Uma M. Borate, Alice S. Mims, John C. Byrd, Yazan F. Madanat
Journal: Blood Advances
Blood Adv (2024) 8 (20): 5297–5305.
https://doi.org/10.1182/bloodadvances.2024013685
Published: 2024
Includes: Supplemental data
Journal Articles

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2 -mutant AML

Clinical Trials & Observations
Sheng F. Cai, Ying Huang, Jennie R. Lance, Hsiaoyin Charlene Mao, Andrew J. Dunbar, Samantha N. McNulty, Todd Druley, Yan Li, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark Litzow, Tara Lin, Prapti Patel, Matthew C. Foster, Michael Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy L. Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine, Eytan M. Stein
Journal: Blood Advances
Blood Adv (2024) 8 (2): 429–440.
https://doi.org/10.1182/bloodadvances.2023010563
Published: 2024
Includes: Supplemental data
Journal Articles

Pevonedistat with azacitidine in older patients with TP53 -mutated AML: a phase 2 study with laboratory correlates

Clinical Trials & Observations
Antoine N. Saliba, Scott H. Kaufmann, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Michael Deininger, William Blum, Gary J. Schiller, Rebecca L. Olin, Mark R. Litzow, Tara L. Lin, Brian J. Ball, Michael M. Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha L. Arellano, Alison Walker, Vu H. Duong, Tibor Kovacsovics, Robert H. Collins, Abigail B. Shoben, Nyla A. Heerema, Matthew C. Foster, Kevin L. Peterson, Paula A. Schneider, Molly Martycz, Theophilus J. Gana, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Alice S. Mims, Uma Borate, Amy Burd, Brian J. Druker, Ross L. Levine, John C. Byrd, James M. Foran
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2360–2363.
https://doi.org/10.1182/bloodadvances.2022008625
Published: 2023
Includes: Supplemental data
Journal Articles

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia

Curtis A. Lachowiez, Nicola Long, Jennifer Saultz, Arpita Gandhi, Laura F. Newell, Brandon Hayes-Lattin, Richard T. Maziarz, Jessica Leonard, Daniel Bottomly, Shannon McWeeney, Jennifer Dunlap, Richard Press, Gabrielle Meyers, Ronan Swords, Rachel J. Cook, Jeffrey W. Tyner, Brian J. Druker, Elie Traer
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1899–1909.
https://doi.org/10.1182/bloodadvances.2022009010
Published: 2023
Includes: Supplemental data
Journal Articles

Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia

Stephen E. Kurtz, Christopher A. Eide, Andy Kaempf, Nicola Long, Daniel Bottomly, Olga Nikolova, Brian J. Druker, Shannon K. McWeeney, Bill H. Chang, Jeffrey W. Tyner, Anupriya Agarwal
Journal: Blood Advances
Blood Adv (2022) 6 (10): 3062–3067.
https://doi.org/10.1182/bloodadvances.2021006307
Published: 2022
Includes: Supplemental data
Journal Articles

Replication timing alterations in leukemia affect clinically relevant chromosome domains

Juan Carlos Rivera-Mulia, Takayo Sasaki, Claudia Trevilla-Garcia, Naoto Nakamichi, David J. H. F. Knapp, Colin A. Hammond, Bill H. Chang, Jeffrey W. Tyner, Meenakshi Devidas, Jared Zimmerman, Kyle N. Klein, Vivek Somasundaram, Brian J. Druker, Tanja A. Gruber, Amnon Koren, Connie J. Eaves, David M. Gilbert
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3201–3213.
https://doi.org/10.1182/bloodadvances.2019000641
Published: 2019
Includes: Supplemental data
Journal Articles

Challenges and approaches to implementing master/basket trials in oncology

Clinical Trials & Observations
Amy Burd, Richard L. Schilsky, John C. Byrd, Ross L. Levine, Vassiliki A. Papadimitrakopoulou, Roy S. Herbst, Mary W. Redman, Brian J. Druker, David R. Gandara
Journal: Blood Advances
Blood Adv (2019) 3 (14): 2237–2243.
https://doi.org/10.1182/bloodadvances.2019031229
Published: 2019
Journal Articles

EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT

Akil A. Merchant, Aparna Jorapur, Amy McManus, Ren Liu, Valery Krasnoperov, Parvesh Chaudhry, Mohan Singh, Lisa Harton, Mary Agajanian, Miriam Kim, Timothy J. Triche, Jr, Brian J. Druker, Jeffrey W. Tyner, Parkash S. Gill
Journal: Blood Advances
Blood Adv (2017) 1 (20): 1635–1644.
https://doi.org/10.1182/bloodadvances.2017005694
Published: 2017
Includes: Supplemental data